TWELVE-MONTH EFFICACY OF INTRAVITREAL BEVACIZUMAB INJECTION FOR CHRONIC, ATYPICAL, OR RECURRENT CENTRAL SEROUS CHORIORETINOPATHY.

MLA

Chung, Yoo-Ri, et al. “Twelve-Month Efficacy of Intravitreal Bevacizumab Injection for Chronic, Atypical, or Recurrent Central Serous Chorioretinopathy.” Retina (Philadelphia, Pa.), vol. 39, no. 1, Jan. 2019, pp. 134–42. EBSCOhost, https://doi.org/10.1097/IAE.0000000000001917.

APA

Chung, Y.-R., Kim, J. W., Song, J. H., Park, A., & Kim, M. H. (2019). Twelve-Month Efficacy of Intravitreal Bevacizumab Injection for Chronic, Atypical, or Recurrent Central Serous Chorioretinopathy. Retina (Philadelphia, Pa.), 39(1), 134–142. https://doi.org/10.1097/IAE.0000000000001917

Chicago

Chung, Yoo-Ri, Jong Wan Kim, Ji Hun Song, Aram Park, and Min Ho Kim. 2019. “Twelve-Month Efficacy of Intravitreal Bevacizumab Injection for Chronic, Atypical, or Recurrent Central Serous Chorioretinopathy.” Retina (Philadelphia, Pa.) 39 (1): 134–42. doi:10.1097/IAE.0000000000001917.